Showing results (521-530 of 538) with videos related to

Sort By:
Pageof 54
The Lancet. HIV|December 12, 2024
Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trialSrilatha Edupuganti, Christopher B Hurt, Kathryn E Stephenson, et al.
Plos Pathogens|March 2, 2021
Correction: RV144 HIV-1 vaccination impacts post-infection antibody responsesThembi Mdluli, Ningbo Jian, Bonnie Slike, et al.
Biorxiv : the Preprint Server for Biology|April 29, 2026
Intranasal Replicating Adenovirus type 4-SARS-CoV-2 Recombinants Induce Superior Immune Response Durability and Efficacy in Preclinical Testing Compared to Standard Intramuscular VaccinesBreanna Kim, Rachel Roenicke, Peyton M Roeder, et al.
Science (New York, N.Y.)|July 4, 2015
Protective efficacy of adenovirus/protein vaccines against SIV challenges in rhesus monkeysDan H Barouch, Galit Alter, Thomas Broge, et al.
Plos Medicine|June 24, 2024
Safety and pharmacokinetics of VRC07-523LS administered via different routes and doses (HVTN 127/HPTN 087): A Phase I randomized clinical trialStephen R Walsh, Cynthia L Gay, Shelly T Karuna, et al.
Nature Communications|June 9, 2017
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challengeTodd Bradley, Justin Pollara, Sampa Santra, et al.
Nature Cancer|February 5, 2022
Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunityShelley E Ackerman, Cecelia I Pearson, Joshua D Gregorio, et al.
Iscience|April 20, 2026
Intranasal replicating adenovirus type 4-vectored SARS-CoV-2 vaccines induce durable and efficacious responses in preclinical testingBreanna Kim, Rachel Roenicke, Peyton M Roeder, et al.
The Lancet. HIV|May 29, 2025
Safety, pharmacokinetics, and neutralisation activity of PGDM1400LS, a V2 specific HIV-1 broadly neutralising antibody, infused intravenously or subcutaneously in people without HIV-1 in the USA (HVTN 140/HPTN 101 part A): a first-in-human, phase 1 randomised trialKelly E Seaton, Carmen A Paez, Chenchen Yu, et al.
Cell Reports|May 14, 2020
Co-immunization of DNA and Protein in the Same Anatomical Sites Induces Superior Protective Immune Responses against SHIV ChallengeBarbara K Felber, Zhongyan Lu, Xintao Hu, et al.
Pageof 54